Total Payments
$273,712
2024 Payments
$2,280
Companies
68
Transactions
1,111
Medicare Patients
9,074
Medicare Billing
$613,611
Payment Breakdown by Category
Research$238,922 (87.3%)
Food & Beverage$17,465 (6.4%)
Other$14,879 (5.4%)
Travel$1,699 (0.6%)
Education$502.63 (0.2%)
Consulting$125.00 (0.0%)
Gifts$118.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $238,922 | 107 | 87.3% |
| Food and Beverage | $17,465 | 961 | 6.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,694 | 13 | 5.0% |
| Travel and Lodging | $1,699 | 12 | 0.6% |
| Honoraria | $1,185 | 1 | 0.4% |
| Education | $502.63 | 14 | 0.2% |
| Consulting Fee | $125.00 | 1 | 0.0% |
| Gift | $118.80 | 2 | 0.0% |
Payments by Type
Research
$238,922
107 transactions
General
$34,789
1,004 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $73,365 | 32 | $0 (2020) |
| SANOFI US SERVICES INC. | $66,375 | 32 | $0 (2021) |
| Kowa Research Institute, Inc. | $37,985 | 28 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33,494 | 18 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $13,035 | 79 | $0 (2024) |
| Chiasma, Inc. | $9,885 | 5 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $9,809 | 42 | $0 (2022) |
| Amryt Pharma Holdings Ltd | $6,753 | 10 | $0 (2023) |
| ABBVIE INC. | $5,093 | 62 | $0 (2024) |
| Novo Nordisk Inc | $2,640 | 174 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,280 | 127 | Novo Nordisk Inc ($488.01) |
| 2023 | $4,767 | 130 | Acella Pharmaceuticals, LLC ($1,185) |
| 2022 | $6,926 | 98 | Amryt Pharma Holdings Ltd ($4,967) |
| 2021 | $14,987 | 132 | Chiasma, Inc. ($9,885) |
| 2020 | $47,916 | 144 | Regeneron Pharmaceuticals, Inc. ($21,611) |
| 2019 | $101,976 | 159 | SANOFI US SERVICES INC. ($32,571) |
| 2018 | $40,291 | 124 | SANOFI US SERVICES INC. ($21,969) |
| 2017 | $54,569 | 197 | Regeneron Pharmaceuticals, Inc. ($22,399) |
All Payment Transactions
1,111 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $37.09 | General |
| Category: Automated insulin delivery system | ||||||
| 12/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/05/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $9.84 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/03/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/02/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $2.32 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $0.61 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/20/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $40.27 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $9.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Cardio-renal | ||||||
| 11/12/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $19.95 | General |
| Category: Endocrinology | ||||||
| 11/06/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $31.81 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Bone Health | ||||||
| 10/30/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $9.57 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/30/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Rare Disease | ||||||
| 10/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $30.16 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $10.07 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/15/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Endocrinology | ||||||
| 10/15/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $10.05 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| K-877-302 | Kowa Research Institute, Inc. | $36,833 | 17 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $33,487 | 16 |
| MRD for BI 685509 in DN Patients | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,583 | 2 |
| Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial | Regeneron Pharmaceuticals, Inc. | $22,485 | 6 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | SANOFI US SERVICES INC. | $14,017 | 14 |
| T2DM SOTA | SANOFI US SERVICES INC. | $11,802 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi | SANOFI US SERVICES INC. | $11,603 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function | SANOFI US SERVICES INC. | $10,872 | 7 |
| LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK AND PREVIOUSLY ENROLLED IN THE NEUROCOGNITIVE FUNCTION TRIAL | Regeneron Pharmaceuticals, Inc. | $10,523 | 7 |
| Eff-CVOT | SANOFI US SERVICES INC. | $10,167 | 2 |
| MACRO Registry | Chiasma, Inc. | $9,786 | 4 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | Regeneron Pharmaceuticals, Inc. | $6,870 | 3 |
| MACRO Registry | Amryt Pharma Holdings Ltd | $6,704 | 8 |
| Toujeo Real World Insulin Nai | SANOFI-AVENTIS U.S. LLC | $6,680 | 3 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $6,199 | 2 |
| HOE901 | SANOFI-AVENTIS U.S. LLC | $4,616 | 2 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,640 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu | SANOFI US SERVICES INC. | $1,715 | 1 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers | SANOFI-AVENTIS U.S. LLC | $615.00 | 1 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $599.82 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 918 | 1,728 | $527,187 | $124,755 |
| 2022 | 10 | 1,853 | 3,192 | $609,460 | $144,068 |
| 2021 | 12 | 3,126 | 6,044 | $756,829 | $187,429 |
| 2020 | 16 | 3,177 | 5,864 | $625,111 | $157,359 |
Total Patients
9,074
Total Services
16,828
Medicare Billing
$613,611
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 656 | 1,287 | $418,275 | $99,323 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 98 | $45,080 | $10,827 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $36,190 | $8,358 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 67 | 81 | $16,200 | $3,703 | 22.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 31 | 170 | $11,037 | $2,166 | 19.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 36 | 45 | $405.00 | $378.00 | 93.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 639 | 1,167 | $379,275 | $88,497 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 157 | 205 | $94,300 | $23,767 | 25.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 73 | 73 | $56,210 | $13,603 | 24.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 100 | 132 | $26,400 | $6,324 | 24.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 274 | 523 | $20,920 | $5,012 | 24.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 40 | 185 | $16,835 | $2,413 | 14.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 471 | 808 | $7,272 | $2,403 | 33.0% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2022 | 25 | 25 | $3,125 | $1,032 | 33.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 45 | 45 | $4,050 | $756.00 | 18.7% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2022 | 29 | 29 | $1,073 | $261.58 | 24.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 631 | 1,280 | $401,692 | $99,715 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 118 | 142 | $63,648 | $15,723 | 24.7% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2021 | 209 | 314 | $39,250 | $12,962 | 33.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 67 | 67 | $50,628 | $12,779 | 25.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2021 | 428 | 708 | $63,720 | $11,894 | 18.7% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2021 | 486 | 906 | $33,522 | $8,172 | 24.4% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 288 | 711 | $28,440 | $6,904 | 24.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 100 | 126 | $24,166 | $6,109 | 25.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 646 | 1,367 | $12,303 | $4,098 | 33.3% |
About Dr. Richard Cherlin, M.D
Dr. Richard Cherlin, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Los Gatos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922060219.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Cherlin, M.D has received a total of $273,712 in payments from pharmaceutical and medical device companies, with $2,280 received in 2024. These payments were reported across 1,111 transactions from 68 companies. The most common payment nature is "" ($238,922).
As a Medicare-enrolled provider, Cherlin has provided services to 9,074 Medicare beneficiaries, totaling 16,828 services with total Medicare billing of $613,611. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Los Gatos, CA
- Active Since 04/04/2006
- Last Updated 11/13/2024
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922060219
Products in Payments
- PRALUENT (Biological) $40,537
- SAR439954 (Drug) $22,475
- NO PRODUCT DISCUSSED (Drug) $21,969
- PRALUENT ALIROCUMAB INJECTION (Biological) $21,703
- MYCAPSSA (Drug) $16,539
- TOUJEO (Drug) $11,556
- SAR439977 (Drug) $10,096
- FARXIGA (Drug) $7,784
- Androgel (Drug) $3,605
- TRADJENTA (Drug) $3,323
- BYDUREON (Drug) $2,025
- Ozempic (Drug) $1,197
- NP Thyroid 60 (Drug) $1,185
- Synthroid (Drug) $1,082
- t-slim insulin pump (Device) $1,015
- AFREZZA (Drug) $814.01
- JARDIANCE (Drug) $747.85
- ADLYXIN (Drug) $615.00
- TRULICITY (Drug) $609.13
- NATPARA (Drug) $553.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Los Gatos
Jaisri Maharaj, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $3,855
Endocrinology, Diabetes & Metabolism $3,855
Deepti Pujare
Endocrinology, Diabetes & Metabolism — Payments: $416.30
Endocrinology, Diabetes & Metabolism $416.30
Dr. Philip Miller, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $29.16
Endocrinology, Diabetes & Metabolism $29.16